<DOC>
	<DOCNO>NCT01664910</DOCNO>
	<brief_summary>The goal clinical research study learn dose level inotuzumab ozogamicin ( CMC-544 ) work best give fludarabine bendamustine , without rituximab , stem cell transplant.The safety treatment also study . Fludarabine , bendamustine , rituximab commonly give stem cell transplant . These drug design kill cancerous cell suppress immune system order low risk stem cell transplant rejection . Inotuzumab ozogamicin design kill cancerous cell reduce risk cancer come back .</brief_summary>
	<brief_title>CMC-544 Allogeneic Transplantation CD22 Positive-Lymphoid Malignancies</brief_title>
	<detailed_description>Study Drug Administration : The dose inotuzumab ozogamicin receive depend join study . The first group 2 participant receive low dose level inotuzumab ozogamicin . Each new group receive high dose inotuzumab ozogamicin group , intolerable side effect see . Three ( 3 ) dose level test . For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . On Day -13 , receive inotuzumab ozogamicin vein 1 hour . On Day -6 , admit hospital give fluid vein hydrate . If CD20-positive cancer , receive rituximab vein 4-6 hour . On Days -5 , -4- -3 , receive fludarabine vein 1 hour bendamustine vein 30 minute 1 hour . On Days -2 -1 , receive match unrelated donor 's ( MUD ) stem cell , receive ATG vein 3-4 hour . If receive relate donor 's stem cell , `` rest '' ( receive chemotherapy drug ) . ATG give suppress immune system . Beginning Day -2 , receive tacrolimus continuous ( nonstop ) infusion able take mouth . Tacrolimus give help prevent transplant rejection . On Day 0 , receive stem cell transplant vein . On Days +1 +8 , CD20 positive cancer , receive rituximab vein 4-6 hour . On Days +1 , +3 , +6 , receive methotrexate vein 30 minute . Methotrexate give help prevent graft versus host disease ( GVHD ) . On Day +11 , receive transplant MUD , receive methotrexate vein 30 minute . When able take tacrolimus mouth , take twice day 6 month doctor tell taper ( gradually stop take ) . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . If disease respond treatment get bad , receive rituximab donor lymphocyte infusion contain T-cells vein 10-30 minute . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : Before Day -13 : - Blood ( 4 tablespoon ) draw routine test , test infectious disease , HIV hepatitis , check status disease . - You bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration/biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . - You chest x-ray . - You compute tomography ( CT ) scan neck , chest , abdomen , pelvis . - If doctor think need , positron emission tomography ( PET ) scan . - If Gilbert 's Disease , abdominal ultrasound . As part standard care , remain hospital 3-4 week transplant . After send home hospital , must remain Houston area check infection transplant side effect 3 month transplant . During time , return clinic least 1 time week . The following test procedure perform : - You ask feel side effect may . - Blood ( 2 teaspoon ) draw routine test . About 1 , 3 , 6 , 12 month transplant , doctor think need , Years 2 3 : - You physical exam , include measurement weight . - You ask feel side effect may drug may take . - Blood ( 2 teaspoon ) draw routine test , check status disease , learn transplant take . - If doctor think need , bone marrow aspiration biopsy check status disease , - You CT scan neck , chest , abdomen , pelvis . - If doctor think need , PET scan . Length Study : You study 3 year . You may take study early disease get bad , intolerable side effect , unable follow study direction , doctor think best interest , study stop , choose leave study early . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . If think drop study , please tell study doctor . The doctor tell effect stop treatment . You doctor talk follow-up care test would help . If leave study , test result information remove study record . This investigational study . Inotuzumab ozogamicin FDA approve commercially available . It currently use research purpose . All drug give study FDA approve commercially available . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Age 18 70 year age . 2 . Patients Bcell hematological malignancy eligible allogeneic transplantation . 3 . Patients must fullymatched sibling donor match unrelated donor identify . 4 . Performance score least 80 % Karnofsky 0 2 ECOG . 5 . Left ventricular EF &gt; /= 45 % uncontrolled arrhythmias symptomatic heart disease . 6 . FEV1 , FVC &gt; /= 50 % correct DLCO &gt; /= 50 % . 7 . Serum creatinine &lt; 1.6 mg/dL . Serum bilirubin &lt; 2 mg/dL upper limit normal ( unless due Gilbert 's Disease ; patient disease right upper quadrant ultrasound evaluation treatment ) . 8 . SGPT &lt; 2 X upper limit normal . 9 . Men woman reproductive potential must agree follow accepted birth control method ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . 10 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breastfeed . Pregnancy test require postmenopausal surgically sterilize woman . 1 . Patient active CNS involvement . 2 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 3 . Patients malignancy diagnose within 2 year prior study registration . Skin squamous basal cell carcinoma exception . 4 . Active bacterial , viral fungal infection . 5 . History stroke within 6 month . 6 . History biliary colic attack . 7 . A prior autologous transplant within 3 month study entry allogeneic stem cell transplant . 8 . Serious medical psychiatric illness likely interfere participation clinical study . 9 . Patient receive investigational drug within 3 week study registration . 10 . Serious nonmalignant disease , opinion investigator would compromise protocol objective . 11 . Prior exposure CMC544 within past 6 month . 12 . Established refractoriness CMC544 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>CD22 Positive-Lymphoid Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>CMC-544</keyword>
	<keyword>Inotuzumab Ozogamicin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
	<keyword>Bendamustine HCL</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>SDX105</keyword>
	<keyword>Treanda</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>